BRIEF-Beigene Reports Approval Of Brukinsa In China For Small Lymphocytic Lymphoma

1 Min Read

June 3 (Reuters) - Beigene Ltd:

* BEIGENE ANNOUNCES THE APPROVAL OF BRUKINSA™ (ZANUBRUTINIB) IN CHINA FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA AND RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

* BEIGENE LTD - RECOMMENDED DOSE OF BRUKINSA IN CHINESE PACKAGE INSERT IS 160 MG TWICE DAILY TAKEN ORALLY WITH OR WITHOUT FOOD Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below